1st Quarter - Amendment

GLENMARK PHARMACEUTICALS USA for GLENMARK PHARMACEUTICALS USA

Firm
Client
Income
—
Expenses
$136,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA User Fees, HR 749

Foreign entity interest: Glenmark Pharmaceuticals Inc., USA (GPI) is the North American division of Glenmark Pharmaceuticals Ltd. (GPL), a corporation duly formed under the commercial code of India, with shares listed on the Bombay Stock Exchange and the National Stock Exchange. No other publicity held corporation owns 10% or more interest in GPI. GPL as the upstream foreign parent company has an indirect interest in the issues.

LobbyistCovered position, as disclosed
GRANT ERDEL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 749 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.